. 2021 Feb 8;52(15):3336–3348. doi: 10.1017/S0033291720005498

Table 3.

Summary of between-group differences of secondary trial outcome

Outcome measure	Intention to treat sample								Per protocol sample
	TAU			TD-GCBT			Difference		TAU			TD-GCBT			Difference
	No. M (s.d.)			No. M (s.d.)			Morris' d p		No. M (s.d.)			No. M (s.d.)			Morris' d p
Working life^a
Baseline	534	3.5	(3.1)	527	3.6	(3.2)	–	0.600	534	3.5	(3.1)	527	3.6	(3.2)	–	0.604
Post-treatment	534	3.0	(3.1)	527	2.6	(3.0)	−0.16	0.002	316	3.1	(3.1)	315	2.4	(2.9)	−0.26	0.002
3 months	534	2.7	(3.0)	527	2.4	(3.0)	–	0.753	238	2.6	(3.0)	273	2.5	(2.9)	–	0.814
6 months	534	2.7	(83.0)	527	2.1	(2.9)	−0.22	0.001	204	2.8	(3.0)	229	1.9	(2.7)	−0.32	0.001
12 months	534	3.1	(3.3)	527	2.4	(3.2)	−0.25	<0.001	180	3.3	(3.3)	208	2.0	(2.7)	−0.44	<0.001
Social life^a
Baseline	534	4.6	(3.0)	527	4.7	(3.0)	–	0.965	534	4.6	(3.0)	527	4.7	(3.0)	–	0.946
Post-treatment	534	4.1	(3.1)	527	3.2	(3.0)	−0.33	<0.001	316	4.1	(3.1)	315	2.9	(2.8)	−0.41	<0.001
3 months	534	3.5	(3.1)	527	3.2	(2.9)	–	0.281	238	3.4	(3.2)	273	3.1	(2.9)	–	0.291
6 months	534	3.4	(3.2)	527	2.7	(3.1)	−0.27	<0.001	205	3.6	(3.2)	228	2.6	(2.8)	−0.36	<0.001
12 months	534	3.8	(3.4)	527	2.9	(3.4)	−0.33	<0.001	180	4.0	(3.3)	208	2.6	(3.1)	−0.48	<0.001
Family life^a
Baseline	534	4.6	(3.1)	527	4.8	(3.0)	–	0.437	534	4.6	(3.1)	527	4.8	(3.0)	–	0.430
Post-treatment	534	3.9	(3.1)	527	3.1	(2.9)	−0.33	<0.001	316	4.0	(3.1)	315	2.8	(3.1)	−0.43	<0.001
3 months	534	3.5	(3.1)	527	3.1	(3.1)	–	0.061	238	3.5	(3.1)	273	3.0	(3.0)	–	0.067
6 months	534	3.6	(3.2)	527	2.7	(3.1)	−0.36	<0.001	205	3.6	(3.1)	228	2.6	(2.7)	−0.41	<0.001
12 months	534	3.8	(3.3)	527	2.8	(3.2)	−0.39	<0.001	180	3.9	(3.3)	208	2.5	(2.8)	−0.51	<0.001
Physical^b
Baseline	534	22.4	(4.3)	527	22.1	(4.3)	–	0.327	534	22.4	(4.3)	527	22.1	(4.3)	–	0.327
Post-treatment	534	23.2	(4.5)	527	24.7	(4.6)	0.42	<0.001	316	22.7	(4.6)	315	25.1	(4.7)	0.61	<0.001
3 months	534	23.5	(4.6)	527	24.2	(4.8)	0.23	0.017	238	23.2	(4.8)	273	24.4	(4.9)	0.34	0.004
6 months	534	23.6	(4.5)	527	24.3	(4.4)	0.23	0.008	204	23.1	(4.8)	229	24.7	(4.9)	0.44	0.001
12 months	534	24.2	(5.1)	527	26.4	(5.3)	0.58	<0.001	180	22.7	(5.1)	208	25.6	(5.3)	0.73	<0.001
Psychological^b
Baseline	534	16.9	(3.8)	527	16.9	(3.8)	–	0.578	534	16.9	(3.8)	527	16.9	(3.8)	–	0.578
Post-treatment	534	17.7	(3.9)	527	19.2	(4.0)	0.39	<0.001	316	17.4	(4.2)	315	19.6	(4.0)	0.61	<0.001
3 months	534	18.1	(3.9)	527	18.9	(4.2)	0.21	0.001	238	18.0	(4.0)	273	19.3	(4.2)	0.38	<0.001
6 months	534	18.5	(3.8)	527	19.1	(3.9)	0.16	0.010	205	18.3	(4.2)	228	19.3	(4.2)	0.31	0.008
12 months	534	18.7	(4.4)	527	20.8	(4.6)	0.55	<0.001	180	18.3	(4.4)	208	20.2	(4.6)	0.54	<0.001
Social^b
Baseline	534	9.1	(2.4)	527	9.1	(2.4)	–	0.915	534	9.1	(2.4)	527	9.1	(2.4)	–	0.915
Post-treatment	534	9.4	(3.1)	527	9.8	(3.3)	0.17	0.024	316	9.2	(2.4)	315	10.0	(2.7)	0.31	<0.001
3 months	534	9.5	(2.3)	527	9.7	(2.3)	–	0.110	238	9.3	(2.2)	273	9.8	(2.4)	0.21	0.014
6 months	534	9.5	(2.5)	527	9.7	(2.2)	–	0.263	205	9.6	(2.5)	228	9.8	(2.2)	–	0.467
12 months	534	9.7	(2.2)	527	11.1	(2.6)	0.58	0.005	180	9.3	(2.2)	208	10.0	(2.6)	0.29	0.005
Environment^b
Baseline	534	25.3	(4.5)	527	25.7	(4.6)	–	0.143	534	25.3	(4.5)	527	25.7	(4.6)	–	0.143
Post-treatment	534	25.7	(5.3)	527	27.2	(5.6)	0.24	<0.001	316	25.5	(4.7)	315	27.8	(4.8)	0.41	<0.001
3 months	534	26.1	(4.9)	527	26.9	(5.1)	0.09	0.012	238	26.1	(4.8)	273	27.5	(5.2)	0.15	0.001
6 months	534	26.5	(4.8)	527	27.1	(4.8)	–	0.064	205	26.4	(4.8)	228	27.7	(5.0)	0.19	0.008
12 months	534	27.5	(5.0)	527	31.2	(5.3)	0.72	0.001	180	26.6	(5.0)	208	28.3	(5.3)	0.29	0.001

M, mean; TAU, treatment-as-usual; TD-GCBT, transdiagnostic group cognitive-behavioural therapy; s.d., standard deviation.

Disability domains measured with the Sheehan Disability Scale.

Quality of Life domains measured with the World Health Organization Quality of life Instrument-Abbreviated.